There Are Only 3 Ways To Increase Your IGF-1 (How To Pick The Right One)

Your pituitary gland releases growth hormone in pulses, and those pulses travel through your bloodstream to your liver, where they trigger the production of something called IGF-1, which is insulin-like growth factor 1, the actual molecule responsible for most of growth hormone's effects on body composition, recovery, and cellular repair. That's the full chain. Every growth hormone compound you've ever heard of is just trying to intervene somewhere along that pathway, and where it intervenes determines everything about how it works, how far it can take your IGF-1, and what the risks are.

There are exactly three places you can enter that chain, and once you understand where each category sits, the decision about which one belongs in your protocol essentially makes itself.

The first entry point is at the very top of the system, at the hypothalamus and pituitary. This is where GHRH analogs like Tesamorelin, CJC-1295, and Sermorelin work. GHRH stands for growth hormone-releasing hormone, and these peptides are synthetic versions of the signal your hypothalamus already sends to tell your pituitary to pulse out growth hormone. They don't add growth hormone from the outside. They amplify your own pituitary's output.

The body has a built-in response to this. When IGF-1 rises, the brain releases something called somatostatin, which is essentially a brake signal that tells the pituitary to slow its pulses back down. This feedback loop creates a ceiling. No matter how much GHRH analog you inject, you cannot push IGF-1 beyond what your body will allow before that brake engages. The clinical trials on Tesamorelin in HIV-associated lipodystrophy showed meaningful reductions in visceral fat, with trunk fat decreasing by roughly 15 to 20 percent over 26 weeks, but that was achieved entirely within the body's own regulatory range, not above it.

This is the right category if your goal is restoring growth hormone output that has declined with age or dysfunction, supporting sleep quality, recovery, and modest fat loss, all inside the boundaries your physiology set for you.

The second entry point is at the growth hormone level itself. Exogenous HGH, pharmaceutical injectable growth hormone, skips the pituitary entirely and delivers the signal directly into circulation. Because the source is external, the feedback loop that governs pituitary output no longer acts as a ceiling. Your IGF-1 can climb above whatever your body would produce on its own, because the liver is simply responding to how much GH is present, and you are controlling that number from outside the system.

The tradeoff is that exogenous GH suppresses your pituitary's own output. Research published in the Journal of Clinical Endocrinology and Metabolism showed that exogenous 20K growth hormone suppressed endogenous 22K GH secretion in normal men, and earlier work confirmed that exogenous GH inhibits GHRH-induced GH secretion, meaning the pituitary goes quiet when GH is coming in from outside. This is why the second rule in this system matters so much. If you are already injecting pharmaceutical HGH, adding a GHRH analog on top of it is biologically pointless. Your pituitary is already suppressed. The GHRH analog has nowhere to act. You are paying for a signal your body has already stopped listening to.

Exogenous HGH is the long-term play for sustained IGF-1 above your natural ceiling, and the evidence supports it for body composition. A trial by Johannsson and colleagues found that growth hormone treatment in abdominally obese men reduced abdominal fat mass, improved lipoprotein metabolism, and lowered diastolic blood pressure over six months, with visceral fat responding most strongly. The mechanism there matters: growth hormone drives lipolysis, meaning it breaks down stored fat for energy, and it does so most powerfully at the fat depot with the highest density of GH receptors, which is visceral adipose tissue. This is why Tesamorelin gets labeled a visceral fat peptide based on its trials, but the mechanism is not unique to Tesamorelin. Any compound that raises growth hormone will preferentially mobilize visceral fat through the same GH-mediated lipolysis pathway. The trials just happened to measure visceral fat because that was the relevant outcome in the population being studied.

The third entry point is at the bottom of the chain, bypassing growth hormone entirely. IGF-1 LR3 is a long-acting synthetic version of IGF-1 itself, injected directly. There is no pituitary stimulation, no liver conversion step, no waiting for endogenous GH to do anything. You are placing the end product directly into circulation.

This comes with a specific biological problem. The IGF-1 receptor downregulates with sustained exposure, a process called receptor desensitization, where the cell essentially reduces the number of available receptors in response to chronically elevated ligand concentrations. This is why IGF-1 LR3 has to be cycled, typically at six to eight weeks, with a meaningful break afterward. Research on IGF-1 suppression of GH release also showed that it is free IGF-1, not bound IGF-1, that drives the negative feedback signaling, which matters for understanding how the system responds to direct IGF-1 administration versus the IGF-1 your liver produces bound to carrier proteins. Running IGF-1 LR3 continuously does not produce continuously greater results. It produces diminishing returns followed by receptor blunting, which defeats the entire purpose.

IGF-1 LR3 belongs to someone with a defined short-term goal who is willing to monitor bloodwork closely and understands that this category carries the highest risk profile of the three, precisely because it bypasses every regulatory checkpoint in the system.

None of these three pathways produces fat loss in a caloric surplus. Growth hormone mobilizes stored fat into circulation, but if energy balance is positive, that mobilized fat gets repackaged and stored again. The compound changes where the body looks for fuel and how readily it accesses fat. It does not override the fundamental arithmetic of energy intake versus expenditure.

The system is actually simpler than the marketing around these compounds suggests. Three entry points, three categories, one underlying chain. The question is only where you want to intervene and how far outside your body's own regulation you are willing to go.

---

References

1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357(23):2359-70. DOI: 10.1056/NEJMoa072375
2. Stanley TL, Grinspoon SK. (2015). Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 25(2):59-65. DOI: 10.1016/j.ghir.2014.12.005
3. Moller N, Jorgensen JO. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152-77. DOI: 10.1210/er.2008-0027
4. Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T. (2000). Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. J Clin Endocrinol Metab 85(2):601-6. DOI: 10.1210/jcem.85.2.6377
5. Rosenthal SM, Hulse JA, Kaplan SL, Grumbach MM. (1986). Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men. J Clin Invest 77(1):176-83. DOI: 10.1172/JCI112273
6. Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO. (1998). Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I: evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83(8):2836-42. DOI: 10.1210/jcem.83.8.5040
7. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA. (1997). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82(3):727-34. DOI: 10.1210/jcem.82.3.3809

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness